Europe Radiopharmaceutical Theranostics Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Radiopharmaceutical Theranostics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Radiopharmaceutical Theranostics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Rising prevalence of cancer and other chronic diseases drives demand for targeted radiopharmaceutical therapies.
5.1.3 Technological advancements in imaging and therapy techniques enhance the efficacy of theranostic approaches.
5.1.4 Growing emphasis on personalized medicine promotes the adoption of radiopharmaceutical theranostics.

5.2 Market Opportunities

5.2.1
5.2.2 Expansion of research and development activities in radiopharmaceuticals offers significant growth potential.
5.2.3 Increasing collaboration between pharmaceutical companies and research institutions can accelerate product development.
5.2.4 Opportunities for novel combinations of imaging agents and therapeutic radiopharmaceuticals to enhance treatment outcomes.

5.3 Future Trends

5.3.1
5.3.2 Growing focus on integrating radiopharmaceuticals with advanced imaging technologies for improved diagnostic accuracy.
5.3.3 increased emphasis on developing novel theranostic agents tailored to specific patient profiles and tumor types.
5.3.4 Advancements in regulatory frameworks for radiopharmaceuticals may streamline approval processes and market entry.

5.4 Impact of Drivers and Restraints

6. Europe Radiopharmaceutical Theranostics Market Regional Analysis

6.1 Europe Radiopharmaceutical Theranostics Market Overview

6.2 Europe Radiopharmaceutical Theranostics Market Revenue 2020-2028 (US$ Million)

6.3 Europe Radiopharmaceutical Theranostics Market Forecast Analysis

7. Europe Radiopharmaceutical Theranostics Market Analysis – by Product Type

7.1 Alpha Emitters

7.1.1 Overview
7.1.2 Alpha Emitters: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Beta Emitters

7.2.1 Overview
7.2.2 Beta Emitters: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Positron Emission Tomography Tracers

7.3.1 Overview
7.3.2 Positron Emission Tomography Tracers: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Radiopharmaceutical Theranostics Market Analysis – by Radioisotope

8.1 Technetium-99

8.1.1 Overview
8.1.2 Technetium-99: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.2 Gallium-68

8.2.1 Overview
8.2.2 Gallium-68: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.3 Iodine-131

8.3.1 Overview
8.3.2 Iodine-131: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Iodine-123

8.4.1 Overview
8.4.2 Iodine-123: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Fluorine-18

8.5.1 Overview
8.5.2 Fluorine-18: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Yttrium 90

8.6.1 Overview
8.6.2 Yttrium 90: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.7 Lutetium 177

8.7.1 Overview
8.7.2 Lutetium 177: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.8 Copper 67

8.8.1 Overview
8.8.2 Copper 67: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

8.9 Copper 64

8.9.1 Overview
8.9.2 Copper 64: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Radiopharmaceutical Theranostics Market Analysis – by Source

9.1 Nuclear Reactors and Cyclotrons

9.1.1 Overview
9.1.2 Copper 64: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Radiopharmaceutical Theranostics Market – Europe Analysis

10.1 Europe

10.1.1 Europe Radiopharmaceutical Theranostics Market Breakdown, by Key Country, 2023 and 2028 (%)
10.1.1.1 Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.1.1 UK: Europe Radiopharmaceutical Theranostics Market Breakdown, by Product Type
10.1.1.1.2 UK: Europe Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
10.1.1.1.3 UK: Europe Radiopharmaceutical Theranostics Market Breakdown, by Source

10.1.1.2 Germany: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.2.1 Germany: Europe Radiopharmaceutical Theranostics Market Breakdown, by Product Type
10.1.1.2.2 Germany: Europe Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
10.1.1.2.3 Germany: Europe Radiopharmaceutical Theranostics Market Breakdown, by Source

10.1.1.3 France: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.3.1 France: Europe Radiopharmaceutical Theranostics Market Breakdown, by Product Type
10.1.1.3.2 France: Europe Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
10.1.1.3.3 France: Europe Radiopharmaceutical Theranostics Market Breakdown, by Source

10.1.1.4 Russia: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.4.1 Russia: Europe Radiopharmaceutical Theranostics Market Breakdown, by Product Type
10.1.1.4.2 Russia: Europe Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
10.1.1.4.3 Russia: Europe Radiopharmaceutical Theranostics Market Breakdown, by Source

10.1.1.5 Italy: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.5.1 Italy: Europe Radiopharmaceutical Theranostics Market Breakdown, by Product Type
10.1.1.5.2 Italy: Europe Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
10.1.1.5.3 Italy: Europe Radiopharmaceutical Theranostics Market Breakdown, by Source

10.1.1.6 Rest of Europe: Europe Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Radiopharmaceutical Theranostics Market Breakdown, by Product Type
10.1.1.6.2 Rest of Europe: Europe Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
10.1.1.6.3 Rest of Europe: Europe Radiopharmaceutical Theranostics Market Breakdown, by Source

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Radiopharmaceutical Theranostics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Bayer AG

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 GE Healthcare Technologies Inc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Curium

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Lantheus Medical Imaging, Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Telix Pharmaceuticals Ltd.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Cardinal Health Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Advanced Accelerator Applications S.A

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Theragnostics

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights